Quick Answer
Rein Therapeutics, Inc. reported Total Assets of $24.16 million for the year ending 2025.
- Rein Therapeutics, Inc. showed a decrease of -61.2% in Total Assets from 2024 to 2025.
- This data is from Rein Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $15.11 million | Q3 2017: $59.04 million | Q1 2018: $45.83 million | Q2 2018: $42.58 million | Q3 2018: $38.13 million | Q1 2019: $22.40 million | Q2 2019: $40.19 million | Q3 2019: $33.95 million | Q1 2020: $20.37 million | Q2 2020: $26.13 million | Q3 2020: $22.24 million | Q1 2021: $64.67 million | Q2 2021: $60.53 million | Q3 2021: $54.77 million | Q1 2022: $40.26 million | Q2 2022: $33.77 million | Q3 2022: $27.23 million | Q1 2023: $17.16 million | Q2 2023: $13.99 million | Q3 2023: $12.82 million | Q1 2024: $99.19 million | Q2 2024: $109.40 million | Q3 2024: $104.22 million | Q1 2025: $57.63 million | Q2 2025: $57.48 million | Q3 2025: $53.71 million.
- Over the full 10 years of available data (2016 to 2025), Rein Therapeutics, Inc.'s Total Assets has grown by 9.7%.
- Historical annual values: Fiscal year 2025: $24.16 million | Fiscal year 2024: $62.19 million | Fiscal year 2023: $106.01 million | Fiscal year 2022: $22.01 million | Fiscal year 2021: $48.48 million | Fiscal year 2020: $16.34 million | Fiscal year 2019: $26.47 million | Fiscal year 2018: $30.31 million | Fiscal year 2017: $52.69 million | Fiscal year 2016: $22.02 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: